A light regulatory touch has long attracted companies to establish R&D and manufacturing plants for generic pharmaceuticals in Malta in the knowledge that products developed on the island can be launched globally immediately on the expiry of the originator drug – a massive draw factor for cost- and time-concious generics companies. Building on this…
See Full Report
